Instrument Inactif

Communiqués Alder BioPharmaceuticals, Inc.

Actions

US0143391052

Recherche biotechnologique et médicale

Communiqués

11/10/19	Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC	GL
10/10/19	Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine	GL
16/09/19	Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) on Behalf of Alder Shareholders and Encourages Alder Investors to Contact the Firm	PR
16/09/19	Alder (ALDR) Alert: Johnson Fistel Investigates Proposed Sale of Alder BioPharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal?	PR
16/09/19	Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash	GL
05/09/19	Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society	GL
30/08/19	Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
28/08/19	Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences	GL
06/08/19	Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results	GL
02/08/19	Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
30/07/19	Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2019 Financial and Operating Results	GL
26/07/19	Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
11/07/19	Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention	GL
08/07/19	Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting	GL
19/06/19	Alder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium with Key Opinion Leaders	GL
18/06/19	Alder BioPharmaceuticals® to Present at BMO Capital Markets 2019 Prescription for Success Healthcare Conference	GL
06/05/19	Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials	GL
26/04/19	Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results	GL
26/04/19	Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
22/04/19	U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab	GL
19/04/19	Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
12/04/19	Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
08/04/19	Alder BioPharmaceuticals® Appoints Nadia Dac as Chief Commercial Officer	GL
02/04/19	Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference	GL
05/03/19	Alder BioPharmaceuticals® to Present at the Cowen and Company 39th Annual Health Care Conference	GL